Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation

Lenvatinib, as a multi-kinase inhibitor, has been approved as a first-line drug for patients with advanced hepatocellular carcinoma (HCC). Gasdermin E (GSDME)-mediated pyroptosis, a form of programmed cell death, can be induced by chemotherapy drugs or certain kinase inhibitors. However, the role of...

Full description

Bibliographic Details

Published in:	Cancer Biology & Therapy
Main Authors:	Yuan Yuan, Mu-Ru Wang, Yang Ding, Ya Lin, Ting-Ting Xu, Xing-Xing He, Pei-Yuan Li
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Hepatocellular carcinoma Lenvatinib pyroptosis palmitoylation GSDME
Online Access:	https://www.tandfonline.com/doi/10.1080/15384047.2025.2532217